Menopausal hormone therapy prior to the diagnosis of ovarian cancer is associated with improved survival.

Journal Article (Journal Article)

Purpose

Prior studies of menopausal hormone therapy (MHT) and ovarian cancer survival have been limited by lack of hormone regimen detail and insufficient sample sizes. To address these limitations, a comprehensive analysis of 6419 post-menopausal women with pathologically confirmed ovarian carcinoma was conducted to examine the association between MHT use prior to diagnosis and survival.

Methods

Data from 15 studies in the Ovarian Cancer Association Consortium were included. MHT use was examined by type (estrogen-only (ET) or estrogen+progestin (EPT)), duration, and recency of use relative to diagnosis. Cox proportional hazards models were used to estimate the association between hormone therapy use and survival. Logistic regression and mediation analysis was used to explore the relationship between MHT use and residual disease following debulking surgery.

Results

Use of ET or EPT for at least five years prior to diagnosis was associated with better ovarian cancer survival (hazard ratio, 0.80; 95% CI, 0.74 to 0.87). Among women with advanced stage, high-grade serous carcinoma, those who used MHT were less likely to have any macroscopic residual disease at the time of primary debulking surgery (p for trend <0.01 for duration of MHT use). Residual disease mediated some (17%) of the relationship between MHT and survival.

Conclusions

Pre-diagnosis MHT use for 5+ years was a favorable prognostic factor for women with ovarian cancer. This large study is consistent with prior smaller studies, and further work is needed to understand the underlying mechanism.

Full Text

Duke Authors

Cited Authors

  • Brieger, KK; Peterson, S; Lee, AW; Mukherjee, B; Bakulski, KM; Alimujiang, A; Anton-Culver, H; Anglesio, MS; Bandera, EV; Berchuck, A; Bowtell, DDL; Chenevix-Trench, G; Cho, KR; Cramer, DW; DeFazio, A; Doherty, JA; Fortner, RT; Garsed, DW; Gayther, SA; Gentry-Maharaj, A; Goode, EL; Goodman, MT; Harris, HR; Høgdall, E; Huntsman, DG; Shen, H; Jensen, A; Johnatty, SE; Jordan, SJ; Kjaer, SK; Kupryjanczyk, J; Lambrechts, D; McLean, K; Menon, U; Modugno, F; Moysich, K; Ness, R; Ramus, SJ; Richardson, J; Risch, H; Rossing, MA; Trabert, B; Wentzensen, N; Ziogas, A; Terry, KL; Wu, AH; Hanley, GE; Pharoah, P; Webb, PM; Pike, MC; Pearce, CL; Ovarian Cancer Association Consortium,

Published Date

  • September 2020

Published In

Volume / Issue

  • 158 / 3

Start / End Page

  • 702 - 709

PubMed ID

  • 32641237

Pubmed Central ID

  • PMC7487048

Electronic International Standard Serial Number (EISSN)

  • 1095-6859

International Standard Serial Number (ISSN)

  • 0090-8258

Digital Object Identifier (DOI)

  • 10.1016/j.ygyno.2020.06.481

Language

  • eng